BIOGX, INC

BIOGX, INC. specializes in the manufacturing and production of pharmaceutical and biological products, as indicated by its primary NAICS code 325413. The company’s core capabilities center on the development and scalable production of active pharmaceutical ingredients and biologics, with technical expertise in Good Manufacturing Practices (GMP), process validation, sterile compounding, and quality control systems aligned with FDA 21 CFR Part 211. Their operational focus includes formulation development, lyophilization, aseptic processing, and regulatory documentation support for drug substance and drug product manufacturing. While specific award history is not available, the company’s NAICS classification suggests deep specialization in contract manufacturing services for regulated medical products, with an emphasis on end-to-end production lifecycle management and compliance with current Good Manufacturing Practices. No agency relationships can be inferred due to absence of award data, and no recent contract examples are available to characterize client engagement patterns. The company’s industry focus is firmly rooted in pharmaceutical manufacturing, serving the biopharmaceutical and clinical supply chain sectors through precision production of injectables, vaccines, and other controlled substances. Their market positioning is that of a niche contract development and manufacturing organization (CDMO) with technical rigor in regulated environments. BIOGX, INC. is structured as a small business under the 2L entity classification and operates from its facility in Hoover, Alabama. The company currently holds no federal certifications, including 8(a), HUBZone, or WOSB, and its government market presence is not evidenced by public contract activity. Its operational footprint remains localized, with capacity focused on manufacturing excellence within the pharmaceutical supply chain.